Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Envelope Protein gp120 | 30 | 2023 | 925 | 3.130 |
Why?
|
| HIV-1 | 39 | 2023 | 6963 | 1.730 |
Why?
|
| HIV Antibodies | 12 | 2023 | 1341 | 1.220 |
Why?
|
| HIV Fusion Inhibitors | 8 | 2022 | 82 | 1.180 |
Why?
|
| Middle East | 8 | 2024 | 233 | 1.120 |
Why?
|
| Molecular Mimicry | 8 | 2023 | 213 | 1.020 |
Why?
|
| HIV Envelope Protein gp41 | 11 | 2022 | 306 | 0.980 |
Why?
|
| Virus Internalization | 12 | 2023 | 503 | 0.950 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 6 | 2022 | 381 | 0.920 |
Why?
|
| HIV Infections | 24 | 2023 | 17569 | 0.900 |
Why?
|
| Indenes | 2 | 2022 | 59 | 0.770 |
Why?
|
| Guanidines | 2 | 2022 | 194 | 0.760 |
Why?
|
| Biomimetics | 4 | 2020 | 172 | 0.750 |
Why?
|
| AIDS Vaccines | 3 | 2018 | 900 | 0.700 |
Why?
|
| Anti-HIV Agents | 17 | 2023 | 4573 | 0.670 |
Why?
|
| Antibodies, Neutralizing | 7 | 2020 | 2009 | 0.650 |
Why?
|
| Lentiviruses, Primate | 1 | 2018 | 7 | 0.620 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2017 | 2204 | 0.620 |
Why?
|
| Protein Multimerization | 5 | 2019 | 966 | 0.610 |
Why?
|
| Africa, Northern | 5 | 2020 | 86 | 0.600 |
Why?
|
| Medicine | 1 | 2024 | 945 | 0.520 |
Why?
|
| Harm Reduction | 1 | 2016 | 143 | 0.470 |
Why?
|
| Disease Outbreaks | 1 | 2023 | 1761 | 0.450 |
Why?
|
| Piperazines | 7 | 2020 | 2554 | 0.440 |
Why?
|
| Epidemics | 2 | 2016 | 517 | 0.420 |
Why?
|
| Receptors, CXCR4 | 8 | 2012 | 729 | 0.370 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2016 | 530 | 0.370 |
Why?
|
| Receptors, CCR5 | 7 | 2019 | 491 | 0.360 |
Why?
|
| Culture | 1 | 2014 | 622 | 0.340 |
Why?
|
| Receptors, HIV | 3 | 2023 | 159 | 0.310 |
Why?
|
| Iran | 3 | 2018 | 763 | 0.310 |
Why?
|
| Membrane Fusion | 3 | 2010 | 265 | 0.310 |
Why?
|
| Drug Resistance, Viral | 2 | 2022 | 869 | 0.300 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 3 | 2023 | 306 | 0.290 |
Why?
|
| Phenylalanine | 3 | 2020 | 367 | 0.270 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2006 | 40 | 0.270 |
Why?
|
| Ethers | 1 | 2006 | 73 | 0.270 |
Why?
|
| International Cooperation | 1 | 2013 | 1436 | 0.260 |
Why?
|
| Hepatitis C | 1 | 2016 | 1595 | 0.250 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 5367 | 0.250 |
Why?
|
| Gene Products, env | 1 | 2006 | 250 | 0.250 |
Why?
|
| Protein Conformation | 12 | 2022 | 3956 | 0.240 |
Why?
|
| Health Personnel | 1 | 2018 | 3384 | 0.230 |
Why?
|
| Immunization | 3 | 2018 | 1219 | 0.230 |
Why?
|
| HEK293 Cells | 9 | 2020 | 4280 | 0.230 |
Why?
|
| Women's Health | 1 | 2014 | 2082 | 0.230 |
Why?
|
| Cell Line | 16 | 2020 | 15602 | 0.230 |
Why?
|
| Glycoproteins | 2 | 2022 | 2202 | 0.220 |
Why?
|
| Triazoles | 3 | 2017 | 904 | 0.220 |
Why?
|
| Neutralization Tests | 6 | 2017 | 739 | 0.210 |
Why?
|
| Gene Products, vif | 1 | 2002 | 31 | 0.210 |
Why?
|
| Antiviral Agents | 2 | 2019 | 3072 | 0.210 |
Why?
|
| Protein Binding | 14 | 2023 | 9343 | 0.200 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3115 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3238 | 0.200 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 3415 | 0.200 |
Why?
|
| Virus Attachment | 3 | 2011 | 56 | 0.200 |
Why?
|
| Antigens, Nuclear | 1 | 2002 | 183 | 0.200 |
Why?
|
| Amino Acid Substitution | 4 | 2017 | 1743 | 0.180 |
Why?
|
| Dogs | 6 | 2020 | 3845 | 0.180 |
Why?
|
| Models, Molecular | 10 | 2020 | 5402 | 0.180 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 5520 | 0.170 |
Why?
|
| Thermodynamics | 4 | 2012 | 591 | 0.170 |
Why?
|
| Pandemics | 1 | 2020 | 8747 | 0.170 |
Why?
|
| Humans | 58 | 2024 | 768171 | 0.160 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2017 | 466 | 0.150 |
Why?
|
| Administration, Intravaginal | 1 | 2018 | 149 | 0.150 |
Why?
|
| Drug Design | 4 | 2014 | 1046 | 0.150 |
Why?
|
| Binding Sites | 8 | 2023 | 6019 | 0.150 |
Why?
|
| Chemokines | 3 | 2007 | 963 | 0.150 |
Why?
|
| Giant Cells | 2 | 2017 | 187 | 0.150 |
Why?
|
| Calorimetry | 4 | 2012 | 132 | 0.150 |
Why?
|
| Viral Envelope Proteins | 2 | 2016 | 640 | 0.150 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 966 | 0.140 |
Why?
|
| Sindbis Virus | 1 | 2016 | 36 | 0.140 |
Why?
|
| Macaca mulatta | 3 | 2018 | 2363 | 0.140 |
Why?
|
| Receptors, Virus | 3 | 2011 | 651 | 0.130 |
Why?
|
| Morocco | 1 | 2016 | 36 | 0.130 |
Why?
|
| Structure-Activity Relationship | 8 | 2017 | 3056 | 0.130 |
Why?
|
| Developed Countries | 2 | 2017 | 451 | 0.130 |
Why?
|
| Peptide Fragments | 4 | 2016 | 5151 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2020 | 4415 | 0.130 |
Why?
|
| Haplorhini | 1 | 2016 | 523 | 0.120 |
Why?
|
| Drug Discovery | 2 | 2020 | 1068 | 0.120 |
Why?
|
| Human Rights | 1 | 2018 | 312 | 0.120 |
Why?
|
| Drug and Narcotic Control | 1 | 2016 | 145 | 0.120 |
Why?
|
| Small Molecule Libraries | 2 | 2017 | 742 | 0.120 |
Why?
|
| Epitopes | 3 | 2017 | 2527 | 0.110 |
Why?
|
| Peptides | 3 | 2012 | 4354 | 0.110 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 450 | 0.110 |
Why?
|
| Pyridones | 1 | 2019 | 819 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2016 | 548 | 0.110 |
Why?
|
| Chemokine CXCL12 | 3 | 2011 | 457 | 0.110 |
Why?
|
| Lentivirus | 1 | 2016 | 518 | 0.110 |
Why?
|
| Thymus Gland | 1 | 2018 | 1266 | 0.110 |
Why?
|
| Mice, SCID | 1 | 2018 | 2627 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 1339 | 0.100 |
Why?
|
| Protein Folding | 1 | 2017 | 871 | 0.100 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2017 | 1967 | 0.100 |
Why?
|
| Virus Uncoating | 1 | 2012 | 13 | 0.100 |
Why?
|
| Animals | 15 | 2020 | 169285 | 0.100 |
Why?
|
| Policy Making | 1 | 2016 | 546 | 0.100 |
Why?
|
| Social Stigma | 1 | 2018 | 788 | 0.100 |
Why?
|
| Indans | 1 | 2012 | 92 | 0.100 |
Why?
|
| Risk | 1 | 2023 | 9613 | 0.090 |
Why?
|
| Drug Users | 1 | 2013 | 134 | 0.090 |
Why?
|
| Chemokines, CC | 1 | 2011 | 286 | 0.090 |
Why?
|
| Proteolipids | 1 | 2010 | 112 | 0.090 |
Why?
|
| Oxalates | 2 | 2011 | 99 | 0.090 |
Why?
|
| Hydrocarbons | 1 | 2010 | 105 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2019 | 1982 | 0.080 |
Why?
|
| Virus Replication | 4 | 2019 | 2458 | 0.080 |
Why?
|
| Cytopathogenic Effect, Viral | 2 | 2006 | 152 | 0.080 |
Why?
|
| Capsid Proteins | 1 | 2012 | 468 | 0.080 |
Why?
|
| Ligands | 5 | 2020 | 3284 | 0.080 |
Why?
|
| Bone Marrow | 1 | 2018 | 2935 | 0.070 |
Why?
|
| Rabbits | 1 | 2014 | 4773 | 0.070 |
Why?
|
| Liposomes | 1 | 2011 | 792 | 0.070 |
Why?
|
| Mutation | 4 | 2022 | 30237 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2016 | 2507 | 0.070 |
Why?
|
| Antibodies, Viral | 1 | 2018 | 3214 | 0.070 |
Why?
|
| Recombinant Proteins | 3 | 2015 | 6512 | 0.070 |
Why?
|
| Crystallography, X-Ray | 3 | 2017 | 1951 | 0.060 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2013 | 1354 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2008 | 1162 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 3929 | 0.060 |
Why?
|
| Crystallization | 2 | 2020 | 520 | 0.060 |
Why?
|
| Molecular Weight | 1 | 2006 | 2173 | 0.060 |
Why?
|
| HIV | 2 | 2011 | 1597 | 0.060 |
Why?
|
| Stereoisomerism | 2 | 2019 | 612 | 0.060 |
Why?
|
| Hot Temperature | 1 | 2010 | 1440 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 4055 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 3 | 2006 | 3772 | 0.050 |
Why?
|
| Female | 7 | 2018 | 397187 | 0.050 |
Why?
|
| Amino Acids | 2 | 2007 | 1716 | 0.050 |
Why?
|
| vif Gene Products, Human Immunodeficiency Virus | 1 | 2002 | 51 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2002 | 12171 | 0.050 |
Why?
|
| Receptors, Chemokine | 1 | 2006 | 652 | 0.050 |
Why?
|
| Binding, Competitive | 3 | 2011 | 1142 | 0.050 |
Why?
|
| Liver | 1 | 2018 | 7578 | 0.050 |
Why?
|
| U937 Cells | 1 | 2002 | 260 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 3 | 2016 | 9262 | 0.050 |
Why?
|
| HL-60 Cells | 1 | 2002 | 364 | 0.050 |
Why?
|
| Piperidines | 2 | 2011 | 1667 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 18349 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2017 | 8080 | 0.050 |
Why?
|
| Jurkat Cells | 1 | 2002 | 740 | 0.050 |
Why?
|
| Molecular Conformation | 2 | 2014 | 540 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2015 | 1683 | 0.040 |
Why?
|
| Health Care Sector | 1 | 2020 | 196 | 0.040 |
Why?
|
| Prevalence | 1 | 2016 | 15869 | 0.040 |
Why?
|
| Phenotype | 1 | 2017 | 16726 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2002 | 1228 | 0.040 |
Why?
|
| Time Factors | 2 | 2020 | 40220 | 0.040 |
Why?
|
| Glutaral | 1 | 2018 | 78 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2004 | 1194 | 0.040 |
Why?
|
| Surface Plasmon Resonance | 2 | 2012 | 272 | 0.040 |
Why?
|
| Health Priorities | 1 | 2020 | 380 | 0.040 |
Why?
|
| Documentation | 1 | 2024 | 917 | 0.040 |
Why?
|
| Amino Acid Sequence | 4 | 2016 | 13422 | 0.040 |
Why?
|
| Politics | 1 | 2024 | 822 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2002 | 3074 | 0.030 |
Why?
|
| Antigenic Variation | 1 | 2016 | 117 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2016 | 250 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2016 | 5902 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2017 | 488 | 0.030 |
Why?
|
| Urea | 1 | 2017 | 448 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 6124 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2002 | 2614 | 0.030 |
Why?
|
| Male | 3 | 2018 | 364731 | 0.030 |
Why?
|
| Amino Acid Motifs | 1 | 2017 | 930 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2016 | 24318 | 0.030 |
Why?
|
| Drug Industry | 1 | 2020 | 791 | 0.030 |
Why?
|
| Chemokines, CXC | 2 | 2005 | 420 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2016 | 899 | 0.030 |
Why?
|
| Cold Temperature | 1 | 2017 | 791 | 0.030 |
Why?
|
| Gene Targeting | 1 | 2016 | 841 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2013 | 26421 | 0.030 |
Why?
|
| Reverse Transcription | 1 | 2012 | 48 | 0.030 |
Why?
|
| Genetic Vectors | 2 | 2016 | 3403 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 65379 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2012 | 426 | 0.020 |
Why?
|
| Protein Denaturation | 1 | 2010 | 242 | 0.020 |
Why?
|
| Biological Availability | 1 | 2010 | 391 | 0.020 |
Why?
|
| Health Services Research | 1 | 2017 | 1815 | 0.020 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2012 | 427 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2006 | 17623 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 74944 | 0.020 |
Why?
|
| COS Cells | 1 | 2009 | 1135 | 0.020 |
Why?
|
| Simian immunodeficiency virus | 1 | 2012 | 814 | 0.020 |
Why?
|
| Circular Dichroism | 1 | 2006 | 337 | 0.020 |
Why?
|
| Radioligand Assay | 1 | 2005 | 366 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 1469 | 0.020 |
Why?
|
| Kinetics | 1 | 2012 | 6330 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 2202 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 2005 | 301 | 0.010 |
Why?
|
| Binding Sites, Antibody | 1 | 2004 | 340 | 0.010 |
Why?
|
| Gene Expression | 1 | 2016 | 7601 | 0.010 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 2003 | 96 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2005 | 1065 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 2011 | 1703 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2007 | 1884 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2016 | 6283 | 0.010 |
Why?
|
| Signal Transduction | 3 | 2012 | 23648 | 0.010 |
Why?
|
| Allosteric Regulation | 1 | 2004 | 426 | 0.010 |
Why?
|
| Temperature | 1 | 2009 | 2234 | 0.010 |
Why?
|
| Solubility | 1 | 2004 | 1086 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 3782 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 17142 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2005 | 2179 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2005 | 1337 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2009 | 2592 | 0.010 |
Why?
|
| Cell Death | 1 | 2003 | 1680 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2011 | 6610 | 0.010 |
Why?
|
| Calcium | 1 | 2005 | 5792 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2003 | 19025 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 10266 | 0.000 |
Why?
|
| Mice | 1 | 2011 | 82049 | 0.000 |
Why?
|
Concepts
(218)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(17)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_